Jeremy E. Coffin
University of Iowa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeremy E. Coffin.
American Journal of Pathology | 2004
Anil K. Sood; Jeremy E. Coffin; Galen B. Schneider; Mavis S. Fletcher; Barry R. DeYoung; Lynn M. Gruman; David M. Gershenson; Michael D. Schaller; Mary J.C. Hendrix
Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that is activated by integrin clustering. There are limited data regarding the functional role of FAK in ovarian cancer migration and invasion. In the current study, FAK expression was evaluated in ovarian cell lines (nontransformed and cancer), 12 benign ovarian samples, and in 79 invasive epithelial ovarian cancers. All three ovarian cancer cell lines overexpressed FAK compared to the nontransformed cells. The dominant-negative construct called FAK-related nonkinase (FRNK) was introduced into two ovarian cancer cell lines (SKOV3 and 222). FRNK promoted FAK dephosphorylation without changing total FAK levels in these cell lines. Furthermore, FRNK decreased the in vitro invasive ability of ovarian cancer cells by 56 to 85% and decreased migration by 52 to 68%. FRNK-transfected cells also displayed poor cell spreading. Immunohistochemical analysis revealed that the surface epithelium from all benign ovarian samples had weak FAK expression. In contrast, 68% of invasive ovarian cancers overexpressed FAK. FAK overexpression was significantly associated with high tumor stage, high tumor grade, positive lymph nodes and presence of distant metastasis (all P values <0.05). FAK overexpression was also associated with shorter overall survival (P = 0.008). Multivariate analysis revealed that FAK overexpression and residual disease >1 cm were independent predictors of poor survival. These data indicate that FAK is overexpressed in most invasive ovarian cancers and plays a functionally significant role in ovarian cancer migration and invasion. Thus, FAK may be an important therapeutic target in ovarian carcinoma.
Cancer Biology & Therapy | 2002
Anil K. Sood; Mavis S. Fletcher; Chris M. Zahn; Lynn M. Gruman; Jeremy E. Coffin; Elisabeth A. Seftor; Mary J.C. Hendrix
Vasculogenic mimicry reflects the plasticity of aggressive tumor cells that express vascular cell markers and line tumor vasculature; such has been demonstrated in aggressive ovarian carcinoma. This study measured the clinical significance of tumor cell-lined vasculature in ovarian carcinomas (n = 77), which was detected in 23 (29.8%) tumors. The data show that tumor cell-lined vasculature was associated with aggressive tumor features and with shorter overall survival (p < 0.001). Cox proportional hazards model revealed that tumor cell-lined vasculature (p = 0.002) was independently associated with poor survival. This is the first study demonstrating the clinical implications of tumor cell-lined vasculature in ovarian carcinoma.
Journal of Clinical Investigation | 2013
Myrthala Moreno-Smith; Jyotsnabaran Halder; Paul S. Meltzer; Tamas A. Gonda; Lingegowda S. Mangala; Rajesha Rupaimoole; Chunhua Lu; Archana S. Nagaraja; Kshipra M. Gharpure; Yu Kang; Cristian Rodriguez-Aguayo; Pablo Vivas-Mejia; Behrouz Zand; Rosemarie Schmandt; Hua Wang; Robert R. Langley; Nicholas B. Jennings; Cristina Ivan; Jeremy E. Coffin; Guillermo N. Armaiz; Justin Bottsford-Miller; Sang Bae Kim; Margaret S. Halleck; Mary J.C. Hendrix; William Bornman; Menashe Bar-Eli; Ju Seog Lee; Zahid H. Siddik; Gabriel Lopez-Berestein; Anil K. Sood
Platinum compounds display clinical activity against a wide variety of solid tumors; however, resistance to these agents is a major limitation in cancer therapy. Reduced platinum uptake and increased platinum export are examples of resistance mechanisms that limit the extent of DNA damage. Here, we report the discovery and characterization of the role of ATP11B, a P-type ATPase membrane protein, in cisplatin resistance. We found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin resistance in human ovarian cancer cell lines. ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin in vitro. Combined therapy of cisplatin and ATP11B-targeted siRNA significantly decreased cancer growth in mice bearing ovarian tumors derived from cisplatin-sensitive and -resistant cells. In vitro mechanistic studies on cellular platinum content and cisplatin efflux kinetics indicated that ATP11B enhances the export of cisplatin from cells. The colocalization of ATP11B with fluorescent cisplatin and with vesicular trafficking proteins, such as syntaxin-6 (STX6) and vesicular-associated membrane protein 4 (VAMP4), strongly suggests that ATP11B contributes to secretory vesicular transport of cisplatin from Golgi to plasma membrane. In conclusion, inhibition of ATP11B expression could serve as a therapeutic strategy to overcome cisplatin resistance.
Cancer Biology & Therapy | 2004
Charles N. Landen; Al J. Klingelhutz; Jeremy E. Coffin; Joel I. Sorosky; Anil K. Sood
Introduction: Malignant cells are capable of an unlimited number of cell divisions, either through production of telomerase, or through the alternate lengthening of telomere (ALT) mechanism. Yeast cells with genomic instability have been shown to survive in the absence of telomerase by increased recombination events. We hypothesized that ovarian cancers with high microsatellite instability (MSI-H) are more likely to lack telomerase activation. Methods We examined 104 invasive ovarian cancers for MSI with 6 microsatellite markers (BAT25, BAT26, D5S346, D2S123, D17S250, and NME1). Telomerase activity was determined with ELISA, and its subunits human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR) by RT-PCR. Statistical analysis was performed with Chi-square and p
Infection and Immunity | 2016
Deborah M. B. Post; Margaret R. Ketterer; Jeremy E. Coffin; Lorri M. Reinders; Robert S. Munson; Thomas B. Bair; Timothy F. Murphy; Eric Foster; Bradford W. Gibson; Michael A. Apicella
ABSTRACT Haemophilus haemolyticus and nontypeable Haemophilus influenzae (NTHi) are closely related upper airway commensal bacteria that are difficult to distinguish phenotypically. NTHi causes upper and lower airway tract infections in individuals with compromised airways, while H. haemolyticus rarely causes such infections. The lipooligosaccharide (LOS) is an outer membrane component of both species and plays a role in NTHi pathogenesis. In this study, comparative analyses of the LOS structures and corresponding biosynthesis genes were performed. Mass spectrometric and immunochemical analyses showed that NTHi LOS contained terminal sialic acid more frequently and to a higher extent than H. haemolyticus LOS did. Genomic analyses of 10 strains demonstrated that H. haemolyticus lacked the sialyltransferase genes lic3A and lic3B (9/10) and siaA (10/10), but all strains contained the sialic acid uptake genes siaP and siaT (10/10). However, isothermal titration calorimetry analyses of SiaP from two H. haemolyticus strains showed a 3.4- to 7.3-fold lower affinity for sialic acid compared to that of NTHi SiaP. Additionally, mass spectrometric and immunochemical analyses showed that the LOS from H. haemolyticus contained phosphorylcholine (ChoP) less frequently than the LOS from NTHi strains. These differences observed in the levels of sialic acid and ChoP incorporation in the LOS structures from H. haemolyticus and NTHi may explain some of the differences in their propensities to cause disease.
Archive | 2017
Patrick L. Sinn; Jeremy E. Coffin; Natarajan Ayithan; Kathleen H. Holt; Wendy Maury
Pseudotyping lentivirus-based vectors is a strategy used to study conferred vector tropism and mechanisms of envelope glycoprotein function. Lentiviruses and filoviruses both assemble at the plasma membrane and have homotrimeric structural envelope glycoproteins that mediate both receptor binding and fusion. Such similarities help foster efficient pseudotyping. Importantly, filovirus glycoprotein pseudotyping of lentiviral vectors allows investigators to study virus entry at substantially less restrictive levels of biosafety containment than that required for wild-type filovirus work (biosafety level-2 vs. biosafety level-4, respectively). Standard lentiviral vector production involves transient transfection of viral component expression plasmids into producer cells, supernatant collection, and centrifuge concentration. Because the envelope glycoprotein expression plasmid is provided in trans, wild type or variant filoviral glycoproteins from marburgvirus or ebolavirus species may be used for pseudotyping and compared side-by-side. In this chapter we discuss the manufacture of pseudotyped lentiviral vector with an emphasis on small-scale laboratory grade production.
Clinical Cancer Research | 2003
Susan K. Lutgendorf; Steven W. Cole; Erin S. Costanzo; Sarah Bradley; Jeremy E. Coffin; Sarvenaz Jabbari; Kaitlin Rainwater; Justine M. Ritchie; Maria Yang; Anil K. Sood
Clinical Cancer Research | 2002
Anil K. Sood; Mavis S. Fletcher; Lynn M. Gruman; Jeremy E. Coffin; Sarvenaz Jabbari; Zhila Khalkhali-Ellis; Nancy C. Arbour; Elisabeth A. Seftor; Mary J.C. Hendrix
Clinical Cancer Research | 2002
Brian C. Cooper; Justine M. Ritchie; Carrie L W Broghammer; Jeremy E. Coffin; Joel I. Sorosky; Richard E. Buller; Mary J.C. Hendrix; Anil K. Sood
American Journal of Obstetrics and Gynecology | 2004
Anil K. Sood; Mavis S. Fletcher; Jeremy E. Coffin; Maria Yang; Elisabeth A. Seftor; Lynn M. Gruman; David M. Gershenson; Mary J.C. Hendrix